Niramai Health Analytix raises $6 million in Series A funding round
Niramai Health Analytix Pvt Ltd, Breast cancer screening startup, has raised $6 million in a Series A round of funding led by Dream Incubator, the Tokyo-headquartered management consulting firm.
This round has also seen participation from Singapore-based venture fund Beenext and existing investors pi Ventures, Ankur Capital, Axilor Ventures and Binny Bansal.
The fresh capital will be used by the startup to scale its operations in India, hire top talent and get additional regulatory approvals for global expansion.
Dr. Geetha Manjunath, CEO & CTO of Niramai, said, “Niramai helps to bridge the gap in our healthcare delivery systems by providing an AI tool that is accurate, affordable and accessible to all. If institutionalised as a regular screening method, NIRAMAI Thermalytix has the potential to save many lives not just from breast cancer deaths but eventually other diseases as well. We are thankful for the continued support and mentorship provided by our seed investors and is excited to join hands with our new investors to propel us to the next level of growth.”
Manish Singhal, Founding Partner, pi Ventures, stated, “We believe that Niramai’s team and technology will create a significant difference in early detection of breast cancer and are happy to continue backing them in their journey. AI diagnostic tools are helping doctors scour through data to better diagnose a variety of abnormal conditions and is the only way to bridge the huge demand and supply gap when it comes to quality healthcare.”